Objective
Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such as insufficient knowledge on risk factors that contribute to PCa and on patient characteristics (including genetic profiles) that could facilitate patient stratification. Finally, there is lack of meaningful engagement of all key stakeholders, while the knowledge currently gained from clinical practice and real life data is not being fed back into PCa patients’ care pathways. There is thus a need for better definition of PCa across all stages, improved patient’s stratification at diagnosis, and standardisation of PCa-related outcomes based on real life data.
PIONEER’s unique dual approach is to first identify critical evidence gaps in PCa by respected Key Opinion Leaders, and then embark on a research priority setting exercise that reflects the needs of all key stakeholders in PCa management. To achieve this, PIONEER has brought together comprehensive datasets that consists of the most relevant prostate clinical trials and registries, large epidemiological cohorts, electronic heath records, and real-life data from different European (and non-European) patient populations. These unique data sets will be integrated, standardised, harmonised and analysed using approaches that are built on our experience of similar previous IMI projects i.e EMIF, and eTRIKS, and analysed using a unique set of methodologies and advanced analytics methods (OMOP, eHS). PIONEER has already performed a first PCa research priority setting survey, where major stakeholders were asked to identify the current unmet needs in PCa. The five most important open questions will be used as pilot studies to verify PIONEER’s research framework. As such, PIONEER’s deliverables will be outcome-driven, value-based and patient-centric, and relevant to all key stakeholders, as they would have been meaningfully involved from the inception of the project.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6842 CV Arnhem
Netherlands
See on map
Participants (37)
22100 Lund
See on map
20132 Milano
See on map
3015 GD Rotterdam
See on map
20251 Hamburg
See on map
33100 Tampere
See on map
WC2R 2LS London
See on map
1200 Brussels
See on map
2289 DC Rijswijk
See on map
NW1 2DN London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1210 Bruxelles
See on map
69390 Vourles
See on map
SW7 2AZ London
See on map
3511 MJ Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2000 Maribor
See on map
EC2A 4ES London
See on map
Participation ended
BS8 2HL Bristol
7610001 Rehovot
See on map
AB24 3FX Aberdeen
See on map
01069 Dresden
See on map
80686 Munchen
See on map
405 30 Goeteborg
See on map
Participation ended
6525 XZ Nijmegen
223 61 Lund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
51373 Leverkusen
See on map
91380 Chilly Mazarin
See on map
Participation ended
64289 Darmstadt
2333 BE Leiden
See on map
3080 Tervuren
See on map
2340 Beerse
See on map
HG3 IPY Harrogate
See on map
02200 Espoo
See on map
NI 9JY London
See on map
BS2 8HU Bristol
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
3703 CD Zeist
151 85 Sodertaelje
See on map
01328 Dresden
See on map
6525 GA Nijmegen
See on map